Pumpinheart

Pumpinheart is developing a transcatheter deliverable heart pump to treat diastolic heart failure with preserved ejection fraction (HFpEF). Interventional cardiologists need a tool to treat HFpEF patients and millions of patients want to survive advanced stage HFpEF and return home to lead active and fulfilling lives.

HFpEF currently accounts for approximately 50% of all the cases of HF and is estimated to cost the US healthcare system $26.55bn by 2030, $21.24bn of which is expected to be spent on hospitalisation alone. Hospital systems worldwide want relief from the $100bn burden of cost of care of advanced stage HFpEF patients due to associated capped reimbursement schemes and rehospitalisation penalties. This is an unmet need of > two million advanced stage patients and, in Canada, USA, EU and UK, a $32bn TAM, $8bn SAM and $3.2bn OAM, where these patients, being elderly, would be treated free of charge.

The device is a multi-award winning novel transcatheter transfermoral transseptal implantable ECG gated pulsatile diastolic heart pump.

Promoters

Current status

  • Patent filed
  • In vivo proof of concept
  • Raised seed round

Next steps

  • Seeking €5m to fund preclinical design freeze in 2025 of an acute transapical version of device and a Series A is planned for a further €5m to fund preparation and execution of an acute first in human clinical trial in 2026.

pumpinheart animation

Spin-out summary – Pumpinheart PDF | 981.1 KB